Details
|
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the development of innovative cancer treatments. The company’s product candidates include monoclonal antibodies, therapeutic vaccines, and small molecules to treat different kinds of cancer. The Dendreon’s leading product candidate is Provenge, which is a cancer immunotherapy in phase 3 clinical trial for the treatment of androgen independent prostate cancer. Also, the company completed phase 1 clinical trials forvaccine Nauvenge-apc8024, which uses for treatment of ovarian, breast, and other solid tumors. Dendreon is also conducting phase 2 trials of Neuvenge in women with metastatic breast cancer. It has research and development alliances with Genentech, Inc; Abgenix, Inc and DYAX Corp. The company was established in 1992 and is located in Seattle, Washington.
|
